(Total Views: 808)
Posted On: 04/23/2020 5:09:25 PM
Post# of 145890
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
And another article today:
https://www.sfchronicle.com/health/article/Tw...219896.php
Two drugs studied in Bay Area could lessen coronavirus deaths, hospitalizations
Photo of J.D. Morris
J.D. Morris April 23, 2020 Updated: April 23, 2020 6:25 a.m.
A man wearing a mask walks in Alamo Square Park across from the Painted Ladies, a row of historical Victorian homes in San Francisco. Two treatments being studied in the city could show promise against the coronavirus and COVID-19, the deadly disease it causes.
An image shows monoclonal antibodies at work in the body. These manufactured immune system proteins, which are designed to attack specific targets, are used to treat cancer and other disorders. One is being tested against the coronavirus.
Two drugs being studied by Bay Area doctors for use in fighting coronavirus infections may keep more COVID-19 patients alive and out of the hospital if proved effective.
One of the drugs, colchicine, is a cheap and common anti-inflammatory treatment for gout. UCSF is using it in a clinical trial of COVID-19 patients that is occurring entirely remotely. Patients receive colchicine or placebo pills in the mail and do not need to be seen in person.
The other drug, leronlimab, is a newer experimental treatment that was originally developed for use on HIV patients before being tested more recently on some people with breast cancer. Leronlimab is a monoclonal antibody made by the Vancouver, Wash., company CytoDyn, whose chief science officer is based in San Francisco.
Follow J.D. on:
thejdmorris
J.D. Morris is a business reporter covering energy, including PG&E, Tesla and California’s clean power initiatives.
https://www.sfchronicle.com/health/article/Tw...219896.php
Two drugs studied in Bay Area could lessen coronavirus deaths, hospitalizations
Photo of J.D. Morris
J.D. Morris April 23, 2020 Updated: April 23, 2020 6:25 a.m.
A man wearing a mask walks in Alamo Square Park across from the Painted Ladies, a row of historical Victorian homes in San Francisco. Two treatments being studied in the city could show promise against the coronavirus and COVID-19, the deadly disease it causes.
An image shows monoclonal antibodies at work in the body. These manufactured immune system proteins, which are designed to attack specific targets, are used to treat cancer and other disorders. One is being tested against the coronavirus.
Two drugs being studied by Bay Area doctors for use in fighting coronavirus infections may keep more COVID-19 patients alive and out of the hospital if proved effective.
One of the drugs, colchicine, is a cheap and common anti-inflammatory treatment for gout. UCSF is using it in a clinical trial of COVID-19 patients that is occurring entirely remotely. Patients receive colchicine or placebo pills in the mail and do not need to be seen in person.
The other drug, leronlimab, is a newer experimental treatment that was originally developed for use on HIV patients before being tested more recently on some people with breast cancer. Leronlimab is a monoclonal antibody made by the Vancouver, Wash., company CytoDyn, whose chief science officer is based in San Francisco.
Follow J.D. on:
thejdmorris
J.D. Morris is a business reporter covering energy, including PG&E, Tesla and California’s clean power initiatives.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)